V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220009398 | 220003818 | 1.54 | 64.5 | Palliative (P) | 2016-07-29 | 2016-07-30 | FCiSt | N | N | 220036556 | DABRAFENIB + TRAMETINIB |
| 220009399 | 220003818 | 1.56 | 61 | Palliative (P) | 2017-05-19 | 2017-10-06 | Capecitabine + Cisplatin + RT | 2 | null | 220036556 | AFATINIB |
| 220009400 | 220021341 | 0 | 0 | null | 2016-01-09 | 2016-01-15 | Bortezomib +/- Dexamethasone | N | N | 220036564 | CARBOPLATIN + PEMETREXED |
| 220009401 | 220021341 | 0 | 56 | Palliative (P) | 2014-01-12 | 2014-01-12 | Carboplatin+Fluorouracil 4 or 5 day | 02 | N | 220036564 | GEMTUZUMAB OZOGAMICIN |
| 220009402 | 220022037 | 1.74 | 60.5 | Curative (C) | 2018-02-11 | 2018-02-25 | ALL UKALL2011 IndB Std Dex (PegAsp) | 02 | N | 220036566 | METHOTREXATE INTRATHECAL |
| 220009403 | 220003819 | null | 33.7 | null | 2014-05-13 | 2014-05-14 | BOSUTINIB | N | N | 220036569 | BORTEZOMIB |
| 220009404 | 220003820 | null | null | Curative (C) | 2014-03-21 | 2014-03-21 | FEC 60 or 75 | N | N | 220036573 | CYTARABINE + ETOPOSIDE + IDARUBICIN |
| 220009405 | 220003821 | 1.7 | 55.6 | Curative (C) | 2013-11-20 | 2013-11-21 | THALIDOMIDE | N | N | 220036575 | CISPLATIN |
| 220009406 | 220003822 | 1.67 | 78 | Curative (C) | 2017-01-25 | 2017-01-25 | UKALL14- Ph 1 Induction | 2 | N | 220036577 | IDARUBICIN |
| 220009407 | 220003823 | null | null | Curative (C) | null | 2014-11-21 | FEC | Y | N | 220036582 | FLUDARABINE + MELPHALAN |
| 220009408 | 220003824 | 1.69 | 70.7 | Palliative (P) | 2013-06-05 | 2013-06-20 | Cisplatin + Pemetrexed | N | N | 220036583 | RUXOLITINIB |
| 220009409 | 220012058 | 1.6 | 8.7 | Adjuvant (A) | null | 2015-04-11 | IDARUBICIN | N | N | 220036586 | CISPLATIN + FLUOROURACIL |
| 220009410 | 220012058 | 1.9 | 69.5 | Disease modification (D) | 2016-03-07 | 2016-03-07 | CYCLOPHOSPHAMIDE + FLUDARABINE | 02 | N | 220036586 | IPILIMUMAB |
| 220009411 | 220012058 | 1.5 | 69 | Curative (C) | null | 2014-09-20 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220036586 | CYTARABINE + MITOXANTRONE |
| 220009412 | 220020534 | 1.81 | 57.9 | Palliative (P) | 2015-10-20 | 2015-10-23 | Alemtuzumab(INTRAVENOUS) | 01 | N | 220036594 | IPILIMUMAB |
| 220009413 | 220020534 | null | null | Palliative (P) | 2017-09-24 | 2017-10-03 | BOSUTINIB | N | N | 220036594 | VE |
| 220009414 | 220003825 | null | 104 | Palliative (P) | 2014-03-26 | 2014-03-28 | Cisplatin +Fluorouracil (3 wk) | null | null | 220036603 | CISPLATIN + ETOPOSIDE |
| 220009415 | 220012059 | null | 123 | Curative (C) | 2017-11-02 | 2017-11-04 | Alemtuzumab cond (RI ALLO CAMP100) | 02 | N | 220036604 | CYCLOPHOSPHAMIDE |
| 220009416 | 220012059 | null | null | Curative (C) | 2013-09-19 | 2013-09-30 | Irinotecan + Modified De Gramont | N | N | 220036604 | CISPLATIN |
| 220009418 | 220020535 | 1.7 | 105 | Palliative (P) | 2015-03-09 | 2015-03-09 | Methotrexate intrathecal | Y | N | 220036609 | IPILIMUMAB + NIVOLUMAB |
| 220009419 | 220003826 | 1.77 | 58 | Palliative (P) | 2016-07-09 | 2016-07-18 | Capecitabine + Streptozocin | 2 | N | 220036610 | LI-1 TRIAL |
| 220009420 | 220012060 | null | null | null | 2013-12-05 | 2013-12-13 | Irinotecan + Modified De Gramont | N | null | 220036611 | DACARBAZINE |
| 220009421 | 220012060 | 1.52 | 6.9 | Palliative (P) | 2015-10-03 | 2015-10-08 | Cyclophosphamide + Docetaxel | N | N | 220036611 | CAPECITABINE |
| 220009422 | 220012060 | 1.59 | null | Adjuvant (A) | null | 2012-05-01 | Methotrexate High Dose (3g/m2) | null | null | 220036611 | FCR |
| 220009423 | 220003827 | 1.9 | 0 | Disease modification (D) | 2017-11-24 | 2017-11-26 | IDARUBICIN + MITOXANTRONE + Tretinoin | N | N | 220036620 | DABRAFENIB + TRAMETINIB |
| 220009424 | 220012061 | 1.79 | null | null | null | 2016-08-23 | ALL UKALL60+ TRIAL | null | null | 220036624 | FCR |
| 220009425 | 220003828 | 0 | 0 | Curative (C) | 2014-11-02 | 2014-11-02 | Irinotecan + Modified De Gramont | 02 | Y | 220036625 | BOSUTINIB |
| 220009426 | 220003828 | null | null | null | 2014-07-06 | 2014-07-12 | Fludarabine + Melphalan RIC Allo | N | N | 220036625 | ALEMTUZUMAB |
| 220009427 | 220016521 | 1.58 | 66.2 | Curative (C) | 2017-04-05 | 2017-05-16 | LIPOSOMAL DOXORUBICIN | N | N | 220036629 | ALEMTUZUMAB |
| 220009428 | 220003829 | 1.68 | 85.5 | Curative (C) | 2014-09-28 | 2014-09-29 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 2 | N | 220036632 | DOXORUBICIN |
| 220009429 | 220003830 | 1.66 | 54 | Not known (9) | 2016-10-07 | 2016-10-13 | OCTREOTIDE | Y | N | 220036633 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 220009430 | 220003831 | 1.56 | 51.9 | Disease modification (D) | 2015-06-24 | 2015-06-24 | Cisplatin + Pemetrexed | 02 | N | 220036637 | LENALIDOMIDE |
| 220009431 | 220003831 | 1.79 | null | Curative (C) | 2015-11-29 | 2015-12-21 | ETOPOSIDE + IFOSFAMIDE | N | N | 220036637 | FLUDARABINE + MELPHALAN |
| 220009432 | 220003832 | null | 101.6 | Curative (C) | 2015-05-06 | 2015-05-25 | LANREOTIDE | 2 | N | 220036640 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 220009433 | 220003832 | null | 86.2 | null | 2014-04-14 | 2014-05-14 | IPILIMUMAB + NIVOLUMAB | N | N | 220036640 | FLUDARABINE + MELPHALAN |
| 220009434 | 220003833 | 1.69 | 53.5 | Not known (9) | 2018-01-27 | 2018-01-31 | Cytarabine intrathecal | N | N | 220036645 | CLOFARABINE + CYTARABINE |
| 220009435 | 220003834 | 1.65 | 80.1 | Palliative (P) | 2017-03-27 | 2017-04-03 | Bortezomib +/- Dexamethasone | N | N | 220036646 | LENALIDOMIDE |
| 220009436 | 220003835 | null | 97 | null | 2013-12-04 | 2013-12-04 | Mitoxantrone | 2 | N | 220036648 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220009437 | 220003836 | 1.49 | 0 | Disease modification (D) | 2017-01-30 | 2017-01-31 | Dacarbazine | N | N | 220036649 | RUXOLITINIB |
| 220009438 | 220003837 | null | 82.4 | Palliative (P) | 2017-01-06 | 2017-01-09 | ECarboX | null | null | 220036653 | CETUXIMAB + IRINOTECAN + MDG |
| 220009439 | 220003838 | null | 80 | Curative (C) | 2015-01-06 | 2015-01-22 | Dacarbazine | N | N | 220036654 | CYTARABINE + DAUNORUBICIN + ETOPOSIDE |
| 220009440 | 220003839 | 1.61 | 68 | Adjuvant (A) | 2015-01-21 | 2015-01-29 | CYTARABINE + MITOXANTRONE | N | N | 220036655 | CISPLATIN + PEMETREXED |
| 220009441 | 220003839 | 1.58 | 64.5 | Curative (C) | 2016-12-23 | 2016-12-28 | BUSULFAN + FLUDARABINE + METHOTREXATE | N | N | 220036655 | IDARUBICIN + MITOXANTRONE + TRETINOIN |
| 220009442 | 220003839 | null | 0 | Curative (C) | 2017-12-21 | 2017-12-21 | UKALL 14 TRIAL | N | N | 220036655 | ARSENIC TRIOXIDE + ATRA |
| 220009443 | 220003839 | 1.76 | 53 | Curative (C) | 2017-09-27 | 2017-10-15 | Capecitabine | N | N | 220036655 | CETUXIMAB + RT |
| 220009444 | 220003839 | 1.81 | 0 | Palliative (P) | 2016-05-25 | 2016-05-25 | Capecitabine | N | N | 220036655 | VEMURAFENIB |
| 220009446 | 220012066 | 1.69 | null | null | 2016-06-02 | 2016-06-03 | LANREOTIDE | 99 | N | 220036669 | OCTREOTIDE |
| 220009447 | 220012066 | 1.59 | 65 | Curative (C) | 2015-05-03 | 2015-05-16 | FEC | N | N | 220036669 | ARSENIC TRIOXIDE + TRETINOIN |
| 220009448 | 220003841 | 1.58 | 48.2 | null | 2013-12-03 | 2014-01-07 | Methotrexate High Dose (3g/m2) | N | N | 220036673 | DOCETAXEL |
| 220009449 | 220012067 | 1.77 | 77.5 | Curative (C) | 2017-10-31 | 2017-11-01 | Cisplatin + Pemetrexed | N | N | 220036675 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |